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Lysosomal degradationThe vascular endothelial growth factor (VEGF)-C-induced down-regulation of VEGF receptor (VEG-
FR)-3 is important in lymphangiogenesis. Here, we demonstrate that VEGF-C, -D, and -C156S, but
not VEGF-A, down-regulate VEGFR-3. VEGF-C stimulates VEGFR-3 tyrosyl phosphorylation and tran-
sient phosphorylation of extracellular signal-regulated kinase (ERK), p38, and c-Jun N-terminal
kinases in lymphatic endothelial cells. VEGF-C-induced down-regulation of VEGFR-3 was blocked
by a VEGF-C trap, tyrosine kinase inhibitor, and leupeptin, pepstatin, and E64 (LPE), but was unaf-
fected by Notch 1 activator and c-secretase inhibitors. Our ﬁndings indicate that VEGF-C down-reg-
ulates VEGFR-3 in lymphatic endothelial cells through VEGFR-3 kinase activation and, in part, via
lysosomal degradation.
Published by Elsevier B.V. on behalf of the Federation of European Biochemical Societies.1. Introduction
Vascular endothelial growth factors (VEGFs) are dimeric glyco-
proteins that are critical regulators of hemangiogenesis and lym-
phangiogenesis [1]. The mammalian VEGF family consists of ﬁve
ligands, VEGF-A, -B, -C, -D, and placenta growth factor (PlGF),
and three receptors, VEGFR-1, VEGFR-2, and VEGFR-3, which are
members of the receptor tyrosine kinase superfamily. VEGF-C is a
ligand for VEGFR-3, through which it is capable of inducing both
lymphatic and blood vessel growth in many tissues including the
mouse cornea [2–5]. VEGF-C, when applied to the cornea, induces
corneal neovascularization and lymphangiogenesis by promoting
lymphatic endothelial cell (LEC) proliferation, migration, and tube
formation [6].VEGF-C stimulation of VEGFR-3 leads to the autophosphoryla-
tion of VEGFR-3 intracellular tyrosine residues Y1230 and Y1231,
resulting in binding of the SRC homology-containing signaling
adaptor proteins and growth factor receptor binding protein 2,
which activates extracellular signal-regulated kinase (ERK) 1/2
and PI3K via phosphorylation [7,8]. Alternatively, autophosphory-
lation of the VEGFR-3 tyrosine residue Y1063 induces a survival
signaling cascade via CRKI/II, leading to c-JUN expression [8]. The
ERK and PI3K pathways have been implicated in endothelial cell
(EC) proliferation, migration, and survival, whereas c-Jun is neces-
sary for pro-survival signaling by VEGFR-3 [8–10].
VEGFR-3 activity is implicated in numerous pathologies, includ-
ing chronic inﬂammation, corneal neovascularization and graft
rejection, and tumor growth and metastasis [11,12]. Therefore,
there is clear clinical value in exploring potential therapeutic
approaches to blocking VEGFR-3 activity [13–15]. Experimentally
demonstrated methods for blocking VEGFR-3 signaling include a
recently discovered naturally occurring soluble VEGFR-3 [16], a
synthetic soluble VEGFR-3 fusion protein [17], antibodies against
VEGFR-3 [18,19], small interfering RNAs [20], tyrosine kinase
inhibitors (TKIs) [21], which prevent phosphorylation of the tyro-
sine residues and further downstream signaling, and endostatin-
containing fragments, which can be synthesized with receptor
speciﬁcity [22].
However, little is known about the mechanisms that regulate
VEGFR-3 in vivo. It has been shown that blockade of the Notch sig-
naling pathway, a family of receptors that regulate cell fate deter-
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inhibitor N-[N-(3,5-Diﬂuorophenacetyl)-L-alanyl]-S-phenylglycine
t-butyl ester (DAPT) induces VEGFR-3 transcription in the retina
[19,23]. Although some ﬁndings indicate that Notch may nega-
tively regulate VEGFR-3, another group found that Notch induces
VEGFR-3 expression through a complex with CBF-1/suppressor of
hairless/Lag1 [23]. Moreover, in ECs, Notch can make VEGFR-3
more receptive to VEGF-C, promoting blood EC survival and mor-
phological changes [23]. Thus, the relationship between Notch
and VEGFR-3 appears to be important, but complicated.
Matrix metalloproteinases (MMPs) are generally considered to
be responsible for extracellular matrix remodeling, but recent evi-
dence shows they may also interact with members of the VEGF
family of proteins [24,25]. These relationships remain poorly
understood, but there is evidence for MMP involvement in VEG-
FR-3 signaling. For example, MMP-9 may act through VEGFR-2
and -3 to promote cancer cell migration [26].
An important cellular mechanism used to inactivate proteins,
including receptor tyrosine kinases (RTKs) such as VEGFR-3, is
internalization and degradation. Activated RTKs undergo endocy-
tosis and are, by the clathrin-mediated endosomal pathway, either
recycled to the cell surface or transported to lysosomes for degra-
dation, which represents a form of receptor down-regulation that
can be crucial to the termination of cell proliferation signals pro-
duced by activated receptors [27–29]. Caveolin-1 has speciﬁcally
is involved in the modulation of phosphorylated VEGFR-3 in ECs
during angiogenesis [30] and tumor metastasis [31], strongly sug-
gesting that endocytosis is a normal route for the regulation of
VEGFR-3 activity.
Due to the roles of VEGF–VEGFR interactions in tumor growth
and metastasis, methods for controlling or modulating the VEGF–
VEGFR axis are continuously being studied. Here, we used a variety
of in vitro methods to investigate the mechanisms of VEGFR-3 sig-
naling in ECs.2. Materials and methods
2.1. Cell culture
Simian virus 40 (SV40)-immortalized LECs from mesenchymal
lymphangioblasts (SV-LECs; [32]), vECs [32], and primary human
lung LECs (hLECs, Lonza, Walkersville, MD) were plated onto
100-mm dishes. SV-LEC and hLEC lines were plated at a density
of 5.0  106 cells per 100-mm dish. Cells were starved in serum-
free medium for 24 h prior to experiments. Cells were stimulated
with varying concentrations of VEGF-C (0–200 ng/ml; R&D Sys-
tems, Minneapolis, MN) for 0–24 h, depending on the experiment.
Some experiments also included incubations with VEGF-A, VEGF-
D, VEGFR-3-Fc (all R&D Systems, Minneapolis, MN), GM6001 (Cal-
biochem, Billerica, MA), Jag1 (Anaspec Inc., Fremont, CA), DAPT
(Sigma–Aldrich, St. Louis, MO), AZD2171 (Selleck Chemicals Co.,
Houston, TX), or leupeptin, pepstatin, and E64 (LPE) (Sigma–
Aldrich) for 6 or 24 h, depending on the experiment.
2.2. Western blotting
Conditioned media were collected and concentrated for some
experiments. For cell lysate experiments, cells were lysed in ice-
cold radioimmunoprecipitation assay buffer containing protease
and phosphatase inhibitors (50 mM Tris–HCl, pH 7.4; 150 mM
NaCl; 1% NP40; 0.25% Na-deoxycholate; 1 mM phenylmethylsul-
fonyl ﬂuoride; and Roche complete protease inhibitor), and the
supernatant was collected. Total protein concentration was mea-
sured using a protein assay (Bio-Rad, Hercules, CA) and adjusted
to 1 mg/ml. Proteins were subjected to sodium dodecyl sulfate–polyacrylamide gel electrophoresis (SDS–PAGE) and transferred
to Immobilon P membranes (Millipore, Bedford, MA). Membranes
were blocked with 3% bovine serum albumin and non-fat milk
for 60 min and then incubated for 1 h with anti-VEGFR-3 (rat
anti-mouse, 1:1000, eBiosciences, San Diego, CA). rabbit anti-ERK
(1:1000), mouse anti-phospho-ERK (1:1000), anti-c-Jun N-termi-
nal kinase (JNK) (1:200), mouse anti-phospho-JNK (1:200), anti-
p38 (1:200), or rabbit anti-phospho p38 (1:1000; all Cell Signaling
Technology, Danvers, MA). The membranes were incubated for
30 min with horseradish peroxidase-conjugated donkey anti-rab-
bit, donkey anti-rat, or donkey anti-mouse IgG (1:20000; Cell Sig-
naling Technology or Amersham Biosciences) and washed with
Tris-buffered saline. The target antigen was visualized using the
enhanced chemiluminescence (ECL) detection system (Amersham
Biosciences). To obtain the data shown in Fig. 3A, following
10 min of stimulation with 50 ng/ml VEGF-C, 500 lg cell lysate
was incubated with 1 lg goat anti-human VEGFR-3 (R&D Systems)
for immunoprecipitation before Western blotting with anti-VEG-
FR-3 (rat anti-mouse, 1:1000, eBiosciences) or anti-phosphotyro-
sine 4G10 antibody (1:1000, Millipore, Danvers, MA).
2.3. Reverse transcriptase-polymerase chain reaction (PCR) and real-
time PCR analysis of VEGFR-2 and -3
RNA was puriﬁed from SV-LECs using Trizol reagent (Invitrogen,
Carlsbad, CA) according to the manufacturer’s instructions. RNA
was reverse transcribed using High-Capacity cDNA reverse tran-
scription kit reagents (Applied Biosystems, Foster City, CA). The fol-
lowing primer sets were used for ampliﬁcation: [33] VEGFR-2,
sense 50-AGGTTTGCGTGCTCTTCACAGT-30 and antisense 50-ACA-
CGTAAGAGTCCGGAAGGAA-30; VEGFR-3, sense 50-CCCAGCCATG-
TACAGAAGGT-30 and antisense 50-GGCTGGAGTCAGAGGAGTTG-30;
and glyceraldehyde 3-phosphate dehydrogenase, sense 50-TTGC
CATCAATGACCCCTTCA-30 and antisense 50-ATGGGCTTCCTGTT-
GATGACA-30. Real-time PCR was performed in triplicate using the
ABI Prism 7900HT sequence detection system and SYBR Green
PCR master mix (Applied Biosystems) and the following cycling
conditions: activation of Taq enzyme at 50 C for 2 min, initial
denaturation at 95 C for 10 min, 40 ampliﬁcation cycles of 95 C
for 15 s, and 60 C for 60 s. ABI PRISM SDS 2.3 software (Applied
Biosystems) was used to convert the raw data. VEGFR-2 and -3
mRNA levels were normalized to GAPDH mRNA levels.3. Results
3.1. VEGF-C down-regulates VEGFR-3 protein and mRNA expression in
LECs and vECs
We ﬁrst investigated the effect of VEGF-C stimulation on VEG-
FR-3 expression in immortalized SV-LECs, primary hLECs, and
vECs. VEGFR-3 was detected by Western blotting in untreated
SV-LECs and hLECs, but not in LECs stimulated with 50 ng/ml
VEGF-C for 24 h (Fig. 1A). To determine the circumstances under
which this down-regulation occurs, time- and dose-dependent
studies were performed. VEGFR-3 expression in vECs (Fig. 1B)
was unchanged after 1 h of VEGF-C stimulation, diminished after
5 h of VEGF-C stimulation, and undetectable after 21 h of VEGF-C
stimulation. Dose–response experiments showed that VEGFR-3
expression in SV-LECs remained unaffected by VEGF-C doses of
0.5, 1, or 5 ng/ml, but was diminished by 10 ng/ml VEGF-C and
undetectable after exposure to 50 ng/ml VEGF-C for 24 h
(Fig. 1C).
To determine whether VEGFR-3 protein down-regulation
occurs at the transcriptional level, we analyzed mRNA levels of
VEGFR-2 and -3 in SV-LECs using quantitative real-time PCR.
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LECs, but VEGFR-2 mRNA and control GAPDH mRNA levels were
not altered by VEGF-C stimulation (Fig. 1D). Thus, VEGF-C does
affect VEGFR-3 at both the transcriptional and protein levels,
and although both VEGFR-2 and -3 are receptors for VEGF-C,
VEGFR-2 is likely not down-regulated in the same way as VEG-
FR-3.
3.2. VEGFR-3-speciﬁc ligand, VEGF-C (C156S), down-regulates VEGFR-
3 expression in LECs
To assess the speciﬁcity of the VEGF-C/VEGFR-3 interaction, we
examined whether other VEGFR ligands, such as VEGF-A, -C
(C156S), and -D, exert effects similar to that of VEGF-C on VEG-
FR-3 expression. Stimulation of SV-LECs with VEGF-A for 24 h did
not change VEGFR-3 levels relative to those in untreated SV-LECs.
High concentrations of the VEGFR-3-speciﬁc ligand VEGF-C156S
down-regulated VEGFR-3 expression (200–500 ng/ml), as did low
concentrations of the VEGFR-2 and -3 ligand VEGF-D (20–50 ng/
ml, Fig. 2A). Addition of VEGFR-3-Fc (which sequesters VEGF-C,
preventing it from binding to VEGFRs) to VEGF-C-stimulated LECs
appeared to completely block VEGF-C-induced down-regulation of
VEGFR-3 (Fig. 2B).Fig. 1. VEGF-C treatment down-regulates VEGFR-3 protein and mRNA expression in SV
untreated or stimulated with VEGF-C for 24 h; (B) vECs at the indicated times after VEG
concentrations of VEGF-C for 24 h. (D) Quantitative real-time PCR analysis of VEGFR-2 a3.3. Effect of VEGF-C on distribution of VEGFR-3 in LECs
We then explored whether the distribution of VEGFR-3 is
altered during VEGF-C-induced down-regulation. Fig. 2C shows
that VEGFR-3 was present after 24 h in the lysates of untreated
cells and cells stimulated with a low concentration of VEGF-C
(0.5 ng/ml), whereas stimulation with a high concentration of
VEGF-C (50 ng/ml) reduced VEGFR-3 levels in cell lysates. VEGFR-
3 was undetectable by Western blotting in the conditioned media
of both untreated and stimulated cells. Therefore, VEGF-C does not
induce VEGFR-3 release via exosomes or the release of fragmented
VEGFR-3 into the media. Its decrease in the cell lysate could be due
to several potentially interacting mechanisms, including a reduc-
tion in VEGFR-3 transcription, as shown in Fig. 1D, and a reduction
in VEGFR-3 levels through proteolysis.
3.4. Effects of VEGF-C on VEGFR-3, ERK, p38, and JNK phosphorylation
in SV-LECs
VEGF-C binding induces autophosphorylation of VEGFR-3,
which initiates lymphangiogenesis among LECs. Downstream tar-
gets of pVEGFR-3 include ERK, JNK, and p38. VEGFR-3 tyrosyl phos-
phorylation was examined following immunoprecipitation from-LECs and hLECs. Western blot analysis of VEGFR-3 in: (A) SV-LECs and hLECs left
F-C (50 ng/ml) stimulation; and (C) serum-starved SV-LECs exposed to increasing
nd -3 as well as GAPDH mRNA levels in SV-LECs stimulated with VEGF-C for 24 h.
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phosphorylation was enhanced by VEGF-C stimulation (Fig. 3A,
right panel). Next, the phosphorylation status of ERK, JNK, and
p38 was examined in SV-LECs stimulated with VEGF-C (1 or
50 ng/ml). Maximal levels of phosphorylated ERK were present
5 min after stimulation, whereas JNK and p38 phosphorylation
peaked 5 and 15 min after stimulation, respectively, with 1 or
50 ng/ml VEGF-C. JNK and p38 protein expression levels were
equivalent at all time points, whereas ERK levels appeared to
increase over time following stimulation with 50 ng/ml VEGF-C
(Fig. 3B).
3.5. VEGF-C-induced down-regulation of VEGFR-3 does not require
MMPs or Notch signaling
VEGFR-1 undergoes ectodomain shedding upon PlGF stimula-
tion, and this shedding can be blocked by treatment with
GM6001, a broad inhibitor of metalloproteinase family proteases
[34], indicating that this shedding requires metalloprotease activ-
ity [34]. We tested whether an MMP participates in VEGFR-3 pro-
tein processing by treating SV-LECs with GM6001 and VEGF-C for
24 h. Cells stimulated with VEGF-C displayed the expected down-
regulation of VEGFR-3 relative to untreated cells (Fig. 4A, lane 2
vs. lane 1). Cells that received only GM6001 displayed VEGFR-3
expression similar to that in unstimulated control cells (Fig. 4A,Fig. 2. VEGFR-3 protein expression is down-regulated by treatment with VEGF-C and -D
Western blot analysis of VEGFR-3 in: (A) serum-starved SV-LECs left untreated or stimu
ml) for 24 h; (B) serum-starved SV-LECs untreated or stimulated with VEGF-C for 24 h
conditioned media collected from SV-LECs stimulated with VEGF-C for 24 h.lane 3), but cells receiving VEGF-C and GM6001 exhibited VEG-
FR-3 expression levels equivalent to those in VEGF-C-stimulated
cells (Fig. 4A, lane 4). Therefore, GM6001 inhibition of MMP activ-
ity did not affect the VEGF-C-mediated down-regulation of VEGFR-
3.
Because Singh et al. [16] showed that Notch activation can block
VEGFR-3 expression and that genetic or pharmacological disrup-
tion of Notch signaling enhances endothelial VEGFR-3 expression,
we also analyzed the effect of inhibiting Notch signaling. We found
that neither the Notch1 activator, Jag1 (Fig. 4B, lanes 3–6), nor the
c-secretase inhibitor of Notch, DAPT (Fig. 4B, lanes 7–8), substan-
tially affected VEGF-C-induced down-regulation of VEGFR-3.
3.6. TKI and LPE diminished VEGF-C-induced down-regulation of
VEGFR-3
To investigate whether tyrosine phosphorylation and lysosomal
degradation are involved in VEGF-C-induced down-regulation of
VEGFR-3, we analyzed the effects of a TKI (AZD2171) and lyso-
somal protease inhibitors (LPE) on VEGF-C-induced VEGFR-3
down-regulation. Exposure of hLECs to the TKI (Fig. 4C) or LPE
(Fig. 4D) abolished or partially inhibited VEGF-C-induced VEGFR-
3 down-regulation, respectively. These data conﬁrm that VEGF-C
induces VEGFR-3 down-regulation, at least in part, through activa-
tion of VEGFR-3 and lysosomal protease degradation., but not VEGF-A, and down-regulation by VEGF-C can be blocked by VEGFR-3-Fc.
lated with VEGF-C (C156S, 0–500 ng/ml), VEGF-A (50 ng/ml), or VEGF-D (20–50 ng/
with or without the VEGF-C trap VEGFR-3-Fc (1 lg/ml); and (C) cell lysates and
Fig. 3. VEGF-C induces tyrosyl phosphorylation of ERK, JNK, and p38 in serum-starved SV-LECs. Western blot analysis of: (A) total (left) and tyrosine phosphorylated (right)
VEGFR-3 in SV-LECs left untreated or stimulated with VEGF-C for 10 min; and (B) total (lower rows) and phosphorylated (upper rows) ERK, JNK, and p38 in SV-LECs
stimulated with VEGF-C (1 or 50 ng/ml as indicated) for 0, 5, 15, or 30 min.
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Activation of VEGFR-3 is sufﬁcient for the growth, survival, and
migration of cultured LECs as well as lymphangiogenesis in vivo
[35]. Therefore, down-regulation of the VEGF-C/VEGFR-3 signaling
pathway is a potentially viable method for inhibiting pathogenic
lymphangiogenesis in addition to the growth and metastasis of
tumors, which require access to the blood and lymphatic systems.
We have shown that VEGF-C down-regulates VEGFR-3 protein and
mRNA expression in LECs and vECs in vitro in a time- and concen-
tration-dependent manner. To explore the mechanism by which
this down-regulation occurs, we conducted experiments aimed at
several known upstream effectors and downstream targets of VEG-
FR-3.
First we tested the timing and concentration-dependence of
VEGF-C down-regulation of VEGFR-3. VEGFR-3 down-regulation
was observed after 5 h of incubation with a high dose of VEFG-C
(50 ng/ml, Fig. 1B) and by 24 h with a lower dose (10 ng/ml,
Fig. 1C). Although 50 ng/ml is a high concentration, Weich et al.
(2004) found that transfected human 293 cells secrete up to
50 ng/ml VEGF-C over 6 days in culture [36].
We next explored the speciﬁcity of this interaction. VEGF-C is a
known ligand for both VEGFR-2 and -3, and thus, the inhibitory
effect of VEGF-C on VEGFR-2 was also studied. However, VEGF-C
did not signiﬁcantly down-regulate VEGFR-2 mRNA expression
(Fig 1D). We also tested other ligands to VEGFR-3, as well asVEGF-A, which binds other VEGFRs but not VEGFR-3. Treatment
with 50 ng/ml VEGF-A did not affect VEGFR-3 protein levels
(Fig. 2A), whereas treatment with 200 ng/ml of the VEGFR-3-spe-
ciﬁc VEGF-C (C156S), which does not bind VEGFR-2, reduced VEG-
FR-3 protein levels (Fig. 2A). Treatment with 20 ng/ml VEGF-D, a
separate ligand of both VEGFR-2 and -3, also reduced VEGFR-3 lev-
els, but even at 50 ng/ml, VEGF-D could not reduce VEGFR-3
expression (Fig. 2A) to the degree that VEGF-C did (Fig. 1A–C).
VEGF-D is structurally and functionally similar to VEGF-C (48%
identical, [37]) and binds to the same receptors, but it appears to
play a greater role in the pathology rather than the development
of the lymphatic system [38]. The fact that VEGF-D binding leads
to only partial degradation of VEGFR-3 is interesting, as it supports
the idea that these two ligands have different downstream effects,
even within the same cell and when interacting with the same
receptors. VEGF-C156S, on the other hand, only binds to VEGFR-
3. It induces lymphangiogenesis with less lymphatic sprouting
compared to that induced by VEGF-C and does not exert its effects
through VEGFR-2 as VEGF-C has been shown to [39,21]. Interest-
ingly, the observation that VEGF-C156S had a weaker effect on
VEGFR-3 degradation (Fig. 2C) than VEGF-C (Fig. 1A–C) suggests
that VEGF-C-induced degradation of VEGFR-3 may involve or be
ampliﬁed by an interaction between VEGF-C and VEGFR-2.
We next determined whether the VEGF-C-induced down-regu-
lation of VEGFR-3 could be inhibited by treatment with a soluble
VEGFR-3 (VEGFR-3-Fc, Fig. 2B), which sequesters, or traps, VEGF-
Fig. 4. VEGF-C-induced down-regulation of VEGFR-3 protein expression is not
affected by a MMP inhibitor, Notch 1 activator, or c-secretase inhibitor but is
inhibited by AZD1217 and LPE. Western blot analysis of VEGFR-3 in: (A) serum-
starved SV-LECs treated with either GM6001 (MMP inhibitor, 100 nM), VEGF-C
(50 ng/ml), or both for 24 h; (B) serum-starved SV-LECs left untreated or stimulated
with VEGF-C (50 ng/ml) for 24 h in the presence or absence of the Notch activator,
Jag-1 (1 or 10 lM), or the c-secretase inhibitor, DAPT (10 lM); (C) SV-LECs left
untreated or stimulated with VEGF-C in the presence or absence of the TKI,
AZD2171 (10 or 1 nM); and (D) inhibition of VEGF-C-induced VEGFR-3 down-
regulation by lysosomal protease inhibitors (LPE) after 6 h of incubation.
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FR-3. Our results showed that VEGFR-3-Fc trap treatment abol-
ished VEGF-C-induced VEGFR-3 protein down-regulation,
conﬁrming that the down-regulatory effect on VEGFR-3 occurs
through the ligand binding to VEGFR-3 and not other extraneous
factors. Our ﬁndings suggest that the ligands involved are VEGF-
C and, to a lesser extent, VEGF-D.
A decrease in cellular VEGFR-3 could be accomplished either by
expelling VEGFR-3 from the cell (e.g., via exosomes) or by absorb-
ing and digesting VEGFR-3 within the cell (e.g., by lysosomal deg-
radation). Most growth factors control cellular functions by
activating speciﬁc RTKs. Deactivation of RTKs when they are no
longer required is critical to maintaining normal cellular function
[40], and one major route for cellular protein removal involves
ligand-induced endocytosis of the RTKs and subsequent degrada-
tion of the ligand-activated RTK complex in lysosomes [41]. Wefound that VEGFR-3 was not present in the culture medium before
or after VEGF-C stimulation (Fig. 2C, right lanes), indicating that
VEGFR-3 is not expelled from the cell. Moreover, VEGFR-3 was
present in the cell lysate prior to but not following stimulation
with VEGF-C (Fig. 2C, left lanes), indicating that VEGF-C induces
intracellular degradation of VEGFR-3.
Based on these observations, we analyzed the tyrosine phos-
phorylation and expression of pVEGFR-3, ERK/pERK, JNK/pJNK,
and p38/p-p38, which have all been implicated in lymphangiogen-
esis. VEGF-C stimulation induced VEGFR-3 tyrosyl phosphorylation
(Fig. 3A) and also transiently increased phosphorylation of ERK,
JNK, and p38 (Fig. 3B). However, the level of tyrosyl phosphoryla-
tion of these downstream signaling molecules (ERK, JNK, and p38)
remained relatively unchanged upon treatment with low concen-
trations of VEGF-C, indicating their high sensitivity to this ligand.
The extremely transient nature of these increases (depleted by
30 min post-stimulation), compared to the long time scale over
which VEGF-C induces VEGFR-3 degradation (6–24 h) suggests
that these two effects are likely unrelated.
We next aimed to determine whether known associates of the
VEGF/VEGFR axis, MMPs and Notch, are involved in VEGF-C-
induced degradation of VEGFR-3. An MMP inhibitor (GM6001)
did not affect VEGFR-3 downregulation, indicating that degrada-
tion likely occurs via a separate proteolytic process. Notch proteins
are cell surface proteins that regulate cell fate. Notch can directly
target the VEGFR-3 gene by binding and transactivating the VEG-
FR-3 promoter. However, neither the Notch inhibitor (c secretase
inhibitor DAPT, Fig. 4B) nor the Notch activator Jag1 (Fig. 4B)
showed an effect on VEGFR-3 downregulation in response to
VEGF-C. However, directly blocking VEGFR-3 signal transduction
with the TKI AZD2171 (Fig. 4C) did prevent VEGF-C-mediated
down-regulation of VEGFR-3. Activation of VEGFR-3 autophospho-
rylation upon binding of VEGF-C is therefore essential to the subse-
quent down-regulation of activated VEGFR-3. Lysosomal protease
inhibitors (LPE, Fig. 4D) also inhibited the down-regulatory effect
of VEGF-C, supporting our conclusion that the lysosomal pathway
is involved in this instance of ligand-induced receptor down-
regulation.
Our understanding of the pathways involved in VEGFR inhibi-
tion and promotion is steadily increasing. This task is complicated
by the complexity of the effects of VEGF-C and VEGFR-3 interac-
tions during developmental, normal, pathological, and cancer pro-
cesses and differences across cell types, time points, and
malignancies. Further studies are needed to better deﬁne the pre-
cise mechanisms underlying VEGF-C-induced VEGFR-3 down-reg-
ulation. Understanding this and other methods of molecular
modulation of VEGFR-3 protein levels will aid in the development
of therapeutic interventions for many lymphangiogenesis-related
disorders, including corneal transplant rejection, lymphedema,
and tumor metastasis.
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